September 19, 2014 7:15 AM ET


Company Overview of Virobay Inc.

Company Overview

Virobay, Inc., a clinical-stage pharmaceutical company, develops and commercializes drugs for the treatment of neuropathic pain, autoimmune diseases, and fibrosis. The company is developing VBY-036, a cathepsin S inhibitor, which has completed Phase I clinical trials for the treatment of neuropathic pain and crohn’s disease; and VBY-891, a cathepsin S inhibitor that has completed Phase I clinical trials for the treatment of psoriasis. It is also developing VBY-376, a cathepsin B inhibitor, which has completed a Phase I clinical trial to treat liver fibrosis in patients with nonalcoholic steatohepatitis; and VBY-825, an inhibitor of multiple cathepsins that is in preclinical studies for treat...

1360 Willow Road

Suite 100

Menlo Park, CA 94025

United States

Founded in 2006

8 Employees





Key Executives for Virobay Inc.

Age: 60
Co-Founder and Director
Age: 48
Chief Financial Officer and Senior Vice President
Age: 56
Senior Vice President of Project Management and Operations
Chief Medical Officer
Compensation as of Fiscal Year 2014.

Virobay Inc. Key Developments

Virobay Appoints James Welch as Chief Financial Officer

Virobay Inc. announced the appointment of James Welch as Chief Financial Officer, effective as of June 20, 2014. Prior to joining Virobay, Mr. Welch was Chief Financial Officer at AcelRx Pharmaceuticals.

Virobay Inc. Initiates Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain

Virobay Inc. announced that their development of an oral treatment for pain has reached an important milestone, as Virobay has now initiated a Phase 1 clinical trial of VBY-036 - a selective cathepsin S inhibitor. The first Phase 1 trial of VBY-036 is a double-blind, randomized, placebo-controlled study designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of escalating doses of VBY-036 in healthy adults. The initiation of this Phase 1 trial with VBY-036 represents another significant development objective for Virobay. Virobay also initiated clinical studies with VBY-891, a selective cathepsin inhibitor in March of this year. VBY-891 is being developed in partnership with LEO Pharma for the therapy of dermatological diseases.

Virobay Inc. Presents at BioEquity Europe 2013, May-22-2013 06:00 PM

Virobay Inc. Presents at BioEquity Europe 2013, May-22-2013 06:00 PM. Venue: Sheraton Stockholm, Stockholm, Sweden.

Similar Private Companies By Industry

Company Name Region
Variant Pharmaceuticals, Inc. United States
Chase Pharmaceuticals Corporation, Inc. United States
King Bio, Inc. United States
Arbor Pharmaceuticals, LLC United States
Paxis Pharmaceuticals Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Virobay Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at